Objective: To investigate if the increased proteoglycans in patellar tendinopathy involves a qualitative change in the types of proteoglycans.
C hronic tendinopathy refers to insidious onset of chronic activity-related pain in tendons, and it is now replacing the term tendinosis, which chiefly describes the degenerative changes in the pathological tissues. 1 The clinical manifestation of patellar tendinopathy is localized activity-related pain and swelling over the proximal pole of patellar tendons. The pathogenesis remains speculative. [2] [3] [4] Histopathological studies revealed altered cellularity, hypervascularity, collagen matrix disturbance, and increase of proteoglycan content. 5 Our studies on clinical samples of patellar tendinopathy have found increased proliferation associated with increased expression of platelet-derived growth factor-beta receptor (PDGFRb), 6 increased metalloproteinase (MMP)-1 expression with augmented collagenolysis, 7 and increased transforming growth factor (TGF)-b1 and cyclooxygenase (COX)-2 expression. 8 These findings suggested a healing disturbance in patellar tendinopathy. Further characterization on the histopathological features may add more information for the elucidation of the pathogenesis of patellar tendinopathy.
With respect to proteoglycan deposition in tendinopathy, previous studies mainly employed histological methods to reveal the increase of proteoglycan, 5 but the use of cationic dye binding for measurement cannot distinguish whether proteoglycans are increased or sulfation is increased. Alternative analytical methods of proteoglycans include measurement of uronic acid content, 9 immunolocalization with antibody against glycosaminoglycans (GAG) and various core proteins, 10 and biochemical analysis on GAG with respect to the composition of various sulfated residues by high-performance liquid chromatography (HPLC). 11 However, only a few of these methods had been applied to study increased deposition of proteoglycan in tendinopathy. 9, 12 It is not known whether the disaccharide composition, the sulfation, or just the amount of the original types of proteoglycans was increased. Because GAG chains in proteoglycans are not randomly sulfated and epimerized, different levels of sulfation may be associated with special functions. It is thus important to analyze the composition of GAG disaccharides in order to evaluate the effects of altered proteoglycan levels.
This study aimed at analyzing the proteoglycans in the pathological tissues of patellar tendinopathy as compared to the patellar tendons from healthy controls. The proteoglycan extracts were analyzed by agarose gel electrophoresis to study proteoglycans according to electromobility. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with differential enzymatic digestion by chondroitinase ABC, chondroitinase ACII, and hyaluronidase was used to characterize the types of glycosaminoglycans. We also used reverse-phase HPLC with fluorescence detection to separate and measure chondroitin/dermatan sulfate disaccharide; therefore, the difference in sulfation and disaccharide composition between pathological tissues from patellar tendinopathy and healthy patellar tendons could be detected.
METHODS
All sampling procedures were approved by the Human Research Ethics Committee of the Chinese University of Hong Kong.
Sample Collection
All subjects and controls were recruited from the authors' institution. Twelve patients, 10 men and 2 women with an average age of 31 years (range 15 to 40 years), were included in the current study. All subjects fulfilled the diagnostic criteria of having patellar tendinopathy, with welldefined clinical features, more than 6 months of insufficient nonoperative treatment including physiotherapeutic modalities, and verification by ultrasound or magnetic resonance imaging (MRI). 13 Twelve control subjects, 10 men and two women with an average age of 31 years (range 16 to 38 years), represented patients with anterior cruciate ligament deficiency who were operated on using the healthy patellar tendon as an autograft. The control subjects had no previous history or clinical signs of patellar tendon injury. Patients with patellar tendinopathy and control subjects were informed of the procedures and provided consent before surgery. Guided by the clinical findings and the ultrasound or MRI scans, the pathological patellar tendon tissues was identified and exposed. The macroscopically abnormal region then was removed with a surgical blade while a 0.5 3 1.5 cm piece of tissue was preserved for analysis. In the control subjects, a 0.2 3 0.5 cm piece of healthy patellar tendon was removed from the remnant of the patellar tendon autograft during anterior cruciate ligament reconstruction.
Safranin O Staining and Immunohistochemistry
The tendon specimens were cleansed in sterile saline, fixed in buffered formalin, and then used to prepare 5 mm thick paraffin-embedded sections. After rehydration, standard procedures of hematoxylin and eosin staining and safranin O staining were performed. Immunohistochemical staining was done as described previously. 8 Rabbit monoclonal antihuman decorin and biglycan antibody (kindly provided by Dr. L.W. Fisher, National Institutes of Health) were used at a dilution of 1:400. Negative stain controls were prepared by omitting the primary antibody. After thorough washing with phosphate buffered saline, the sections were incubated with a secondary antibody, biotinylated antimouse immunoglobulin G (DAKO, Glostrup, Denmark). The classic antibody binding complex method was used to amplify the specific binding signal. Finally, 3,3#-diaminobenzidine tetrahydrochloride was used to develop color in the presence of H 2 O 2 . The sections were rinsed in distilled water, counterstained in Mayer's hematoxylin, dehydrated through graded alcohol to xylene, and mounted with p-xylene-bis-pyridinium bromide (DPX) Permount (Sigma Aldrich).
Proteoglycan Extraction
All tendon samples were rinsed thoroughly in sterile saline before deep freezing at -80°C and thawed completely at room temperature prior to analysis. Tendon samples were sliced 20 mm thick by cryostat, lyophilized, weighed, and put for proteoglycan extraction in 4 M Guanidinium chloride for 48 hours (Sigma) with a cocktail of protease inhibitors and detergent according to Hascall VC. 14 
HPLC Analysis of Dermatan Sulfate Disaccharides
Proteoglycans were digested with chondroitinase ABC and ACII (Sigma) to release disaccharides. 14 Analysis of chondroitin sulfate disaccharides was performed by a modified method from Akiyama et al. 11 Twenty microliters of disaccharide solution was mixed with 10 mL 3% trichloroacetic acid in ethanol, 10 mL DDi-UA2S as internal standard, and 10 mL 2% dansylhydrazine in acetonitrile for derivatization in the dark for 120 minutes. After the completion of the reaction, 3 volumes of 1 mL toluene were used to remove excess reactants. It was then injected for HPLC analysis, with an Amido TSK 80 column (Tosoh), a mobile phase of acetonitrile (BDH):acetate buffer (pH 6.0), at a flow rate of 1 mL/min at 45°C. Peaks were resolved with gradient elution from 15% to 23% acetate buffer in 30 minutes, and detected by fluorescence at exl = 340 nm and eml = 525 nm. Chondroitin sulfate disaccharides including DDi-0S, DDi-4S, DDi-6S, DDi-diS B , DDi-diS D , DDi-diS E , and DDi-triS (Sigma) were used for preparing standard curves for quantitative determination.
Electrophoretic Analysis
Before the analysis with SDS-PAGE, the proteoglycan extracts from pathological samples of patellar tendinopathy were subjected to enzymatic digestion with chondroitinase ABC, chondroitinase ACII, or hyaluronidase. Aliquots of 1 mg of proteoglycans extracts from the same sample were separately digested by 0.1 U chondroitinase ABC (Sigma) in 50 mM Tris-HCl, 50 mM sodium acetate (pH 8.0), 0.1 U chondroitinase ACII (Sigma) in 50 mM sodium acetate (pH 6.0), or 0.1 U hyaluronidase (Sigma) in 0.1 M Tris-HCl (pH 6.8) at 37°C for 3 hours. The reaction mixtures was then lyophilized and reconstituted by distilled water immediately before electrophoretic analysis. Prestained low-range molecular weight markers (BioRad; Phosphorylase B 112 kDa, bvine serum albumin 81 kDa, ovalbumin 49.9 kDa, carbonic anhydrase 36.2 kDa, soybean trypsin inhibitor 29.9 kDa, lysozyme 21.3 kDa) were run on all gels. SDS-PAGE with BioRad Minigel electrophoresis system was employed to analyze the digested proteoglycan extracts. With a 5% stacking gel and 10% resolving gel, the proteoglycans were separated and visualized by staining in 0.1% w/v toluidine blue for 20 min and destaining in 20% methanol overnight.
For agarose gel electrophoresis, the proteoglycan extracts from pathological samples and healthy controls were analyzed in a 0.5% agarose gel at 70 V for 1 hour. The gel was then stained in azure A solution (0.08% w/v) for 20 min and destained with 20% methanol overnight.
Statistical Analysis
Due to the variations in the size of the specimens, the collected samples were not sufficient for all histological and biochemical analysis. For the qualitative analysis in electrophoresis, five different samples in each group were processed to confirm the consistency of the findings. For quantitative analysis of dermatan sulfate disaccharides, a nonparametric Mann-Whitney test was used to detect significant difference between pathological samples (n = 4) and healthy controls 
RESULTS
All pathological samples of patellar tendinopathy were positive to varying extents with safranin O staining, but none of the control samples were stained (Fig. 1) . Immunohistochemical staining for decorin and biglycan in pathological samples did not show significant difference from the control (Fig. 2) .
The result of SDS-PAGE electrophoretic analysis of proteoglycan extracts from pathological samples of patellar tendinopathy is shown in Figure 3 With chromatographic analysis of glycosaminoglycans extracted from the tendon samples, it was found that dermatan monosulfate disaccharide and disulfate disaccharide dS B were higher (P = 0.029), but no significant difference was found in other disaccharides (P . 0.05; Fig. 4 ).
Agarose gel electrophoresis revealed that the proteoglycan extracts from pathological samples of patellar tendinopathy (Fig. 5, lanes 4 and 5) were increased and at least three distinct smears of different electromobilities were identified, as compared to one single smear in healthy patellar tendon samples (lanes 6 and 7). Two smears of pathological proteoglycans showed higher electromobilities, whereas one showed a lower electromobility, as compared to the proteoglycans from healthy patellar tendon samples.
DISCUSSION
Increased proteoglycan deposition is identified as one of the main histopathological characteristics for chronic tendinopathy. The increased safranin O staining intensity in patellar tendinopathy samples may be attributed to increased total proteoglycans (increased core proteins), increased glycosaminoglycan content, or increased glycosaminoglycan sulfation. Compositional analysis on GAG extracted from rotator cuff tendinopathy 9 revealed increased hyaluronan, chondroitin sulfate and dermatan sulfate in the supraspinatus tendons from patients with chronic tendinopathy, whereas different tendons showed significantly different composition of GAG. A recent study showed that the mRNA levels of aggrecan and biglycan were significantly increased in Achilles tendinopathy, whereas those of decorin and versican were not significantly changed. 12 These findings indicate that the increased proteoglycan may involve increased core protein synthesis and GAG production. The present study also showed increased GAG, but we did not observe any difference in the immunoreactivity of decorin and biglycan. The discrepancy on the findings on core protein expression may be due to the variations of different tendons as suggested in Riley's study. 9 Our results suggested that the increase in proteoglycans in patellar tendinopathy may be due to increased GAG synthesis, whereas the contribution of increased proteoglycan core protein synthesis may be minimal.
Chondroitinase ACII, which only cleaves at dermatan disaccharides, completely removed the stainability of the proteoglycan smears. It indicates that proteoglycans from pathological tissues of patellar tendinopathy were mainly composed of dermatan proteoglycans. Digestion of pathological proteoglycans with hyaluronidase produced a longer tailing smear, suggesting that the hyaluronic acid content may differ in pathological proteoglycans. Differential enzymatic analysis thus revealed that the GAG side chains of proteoglycans extracted from pathological samples of patellar tendinopathy were mainly composed of dermatan sulfate with variable contents of hyaluronic acid. The types of GAG in pathological proteoglycans were found to be similar to those in healthy tendons.
In the characterization of GAG disaccharides, we found that the amounts of monosulfated dermatan sulfate and disulfate dS B were increased in pathological proteoglycans, but there was no relative decrease in the nonsulfated disaccharides. A net increase of sulfated GAG side chain in pathological proteoglycans was implied, in addition to increased sulfation. Sulfation of glycosaminoglycans was reported to be stimulated by PDGF BB in lung fibroblasts 15 and chain-elongation of GAG can be increased by TGF-b1. 16 Previously, we demonstrated increased PDGFRb 6 and TGF-b 8 in patellar tendinopathy; therefore, it is possible that the increased accumulation of sulfated GAG was due to elevated activities of PDGF BB and TGF-b1. Alternatively, changes in extracellular architecture may influence the expression of dermatan sulfate and dermatan sulfate proteoglycan synthesis, as shown in an in vitro fibroblast model. 17 Agarose electrophoresis revealed that ''new'' proteoglycans were found in the pathological tissues of patellar tendinopathy as compared to control. In contrast to a single smear of proteoglycans extracted from healthy patellar tendons, three smears of different electromobilities were identified in the pathological proteoglycans, with two smears exhibiting higher electromobility and one with lower electromobility. Because the sulfated disaccharides in GAG extracted from pathological samples of patellar tendinopathy were increased as shown by the results of HPLC analysis, the proteoglycan smears with lower electromobility might be larger in size. On the other hand, the proteoglycan smears with higher electromobility may be attributed to increased sulfation (increased negative charges) without significant increase in molecular size. The absence of ''normal'' proteoglycans in the pathological samples of patellar tendinopathy indicated that the increased deposition was not a quantitative increase of original proteoglycans found in healthy tendons. Instead, the proteoglycans in patellar tendinopathy exhibited qualitative changes, with respect to increase in GAG side chain or increase in sulfation. Because increased proteoglycan deposition also was evident in Achilles tendinopathy 11, 18 and rotator cuff tendinopathy, 8 the pathogenesis of tendinopathy in different tendons may share some common pathways. Further quantitative study on proteoglycan synthesis and modification (GAG sulfation) in the pathological tissues may help to elucidate the roles of proteoglycan in the pathogenesis of tendinopathy.
Limitations of the present study include the small sample size and the low proteoglycan content in healthy human patellar tendons. It restricted the quantitative biochemical analyses on the healthy patellar tendons, whereas the clinical samples of patellar tendinopathy usually come with significant size and the proteoglycan content was much higher. Due to the limited availability of samples, only the major proteoglycan core proteins (decorin and biglycan) and GAG (dermatan sulfate, hyaluronic acid) found in tendons were analyzed. Minor proteoglycan core proteins (fibromodulin, aggrecan) and GAG (keratin, heparins) in tendons could not be included, which might yield useful information about the pathological accumulation of proteoglycans in patellar tendinopathy. Because compatible molecular weight standards for sulfated proteoglycans are not available for electrophoretic analysis, the estimation of molecular sizes of the ''new'' proteoglycans in patellar tendinopathy could not be achieved. However, the electromobilities of the proteoglycan smear still convey the biochemical properties such as charge-to-mass ratio.
Proteoglycans are important for the alignment of collagen fibers. 19 Any increase in size or negative charges in proteoglycans may cause disruption of normal architecture of the collagenous matrix in tendons. Altered proteoglycans can modulate cell migration, 20 cell growth, and matrix remodeling. 21 Thus, increased deposition of sulfated proteoglycans may contribute to the failed healing in patellar tendinopathy. Also, increased sulfated proteoglycan might also contribute to the chronic pain. Khan et al 22 suggested that the pain in tendinopathy may be originated from biochemical disturbances, such as substance P. 23 Elevated water retention resulting from accumulation of negatively charged proteoglycans will lead to edematous condition in tendons, which may account for the swollen appearance of the pathological tissues of patellar tendinopathy. It is speculated that the pressure caused by swelling can irritate the nociceptive C-fibers in and around tendons. Increased sulfated GAG proteoglycans also lead to an increase in interstitial counter ion concentrations (K + , H + ), 24 which can also stimulate nociceptive response at C-fibers. Decreasing sulfated proteoglycans may thus present a novel treatment strategy to reduce pain in patellar tendinopathy.
CONCLUSION
The current study revealed that the increased deposition of pathological proteoglycan in patellar tendinopathy was not simply a quantitative change; qualitative changes in the glycosaminoglycans were evident. It suggests an altered metabolic activity in patellar tendinopathy. The deposition of oversulfated proteoglycans may account for the swelling, matrix disturbances, and chronic pain in patellar tendinopathy. FIGURE 5 . Proteoglycan extracts from pathological samples of patellar tendinopathy and healthy patellar tendon samples were analyzed by agarose gel electrophoresis. In lane 1, 1 Kb DNA ladder (Promega) was used to check for standardized electrophoretic conditions. Chondroitin sulfate standards (1 mg) and proteoglycan extracts from articular cartilage (1 mg) were added to lanes 2 and 3, respectively. Proteoglycan extracts (1 mg) from the pathological tissues from two patients of patellar tendinopathy were added to lanes 4 and 5, whereas proteoglycan extracts (1 mg) from two human patellar tendon samples were added to lanes 6 and 7. Three bands were identified in patellar tendinopathy samples, with two bands of higher electromobility and one band with lower electromobility as compared to the single band in healthy patellar tendon samples.
